Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and review - PubMed (original) (raw)
Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and review
D P Roberson et al. Br J Pharmacol. 2011 Sep.
Abstract
Background and purpose: We have developed a strategy to target the permanently charged lidocaine derivative lidocaine N-ethyl bromide (QX-314) selectively into nociceptive sensory neurons through the large-pore transient receptor potential cation channel subfamily V (TRPV1) noxious heat detector channel. This involves co-administration of QX-314 and a TRPV1 agonist to produce a long-lasting local analgesia. For potential clinical use we propose using lidocaine as the TRPV1 agonist, because it activates TRPV1 at clinical doses.
Experimental approach: We conducted experiments in rats to determine optimal concentrations and ratios of lidocaine and QX-314 that produce the greatest degree and duration of pain-selective block when administered nearby the sciatic nerve: reduction in the response to noxious mechanical (pinch) and to radiant heat stimuli, with minimal disruption in motor function (grip strength).
Key results: A combination of 0.5% QX-314 and 2% lidocaine produced 1 h of non-selective sensory and motor block followed by >9 h of pain-selective block, where grip strength was unimpaired. QX-314 at this concentration had no effect by itself, while 2% lidocaine by itself produced 1 h of non-selective block. The combination of 0.5% QX-314 and 2% lidocaine was the best of the many tested, in terms of the duration and selectivity of local analgesia.
Conclusions and implications: Targeting charged sodium channel blockers into specific sets of axons via activation of differentially expressed large-pore channels provides an opportunity to produce prolonged local analgesia, and represents an example of how exploiting ion channels as a drug delivery port can be used to increase the specificity and efficacy of therapeutics.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Figures
Figure 4
The motor and sensory block following injection of 1% lidocaine N-ethyl bromide (QX-314) is abolished when injected in the absence of general anaesthesia. Perisciatic application of 1% QX-314 alone produces prolonged elevation in thermal (radiant heat, 50°C) response latency (A), pinch tolerance threshold (B) and grip weakness (C) only while applied under isoflurane-induced general anaesthesia. Perisciatic injection of 1% QX-314 in non-anaesthetized animals did not change the responses to noxious mechanical and thermal stimuli or grip force. Application of vehicle (0.9% NaCl) administered without general anaesthesia also did not alter motor, mechanical or thermal responsiveness. Values expressed as percent of maximal block (mean ± SEM; *P < 0.01, †P < 0.01,
anova
followed by Dunnett's test; n = 9 for each group). All injections administered at time 0.
Figure 1
The duration of the elevation in thermal response latency (radiant heat, 50°C), pinch tolerance threshold and reduction in grip strength produced following perisciatic injection of lidocaine HCl (1%, 1.5%, 2%) and vehicle (0.9% NaCl) (mean ± SEM; *P < 0.01). All injections administered under isoflurane-induced general anaesthesia at time 0.
Figure 2
The duration of the elevation in thermal (radiant heat, 50°C) response latency (A, D and G), pinch tolerance threshold (B, E and H), and reduction in grip strength (C, F and I) produced following perisciatic (200 µL) injection of lidocaine alone (1%, 1.5% or 2%), 0.5% lidocaine N-ethyl bromide (QX-314) alone, or 0.5% QX-314 administered together with lidocaine (1%, 1.5% or 2%) (mean ± SEM; *P < 0.01). All injections administered under isoflurane-induced general anaesthesia at time 0.
Figure 3
Analysis of the change in grip strength, thermal (radiant heat, 50°C) response latency and pinch tolerance threshold produced following perisciatic injection of varying doses of lidocaine N-ethyl bromide (QX-314) (0%, 0.5%) and lidocaine (0%, 1%, 2%) expressed as total area under the curve (AUC). Note that the value of AUC representing change in pinch tolerance threshold in the group receiving a combined dose of 0.5% QX-314 + 2% lidocaine, is greater than the combined values of corresponding AUCs from the group receiving 0.5% QX-314 alone plus the AUC from the group receiving 2.0% lidocaine alone. Similarly, the AUC value representing change in thermal latency in the group receiving a combined dose of 0.5% QX-314 + 2% lidocaine, is much greater than the combined values of corresponding AUCs from the group receiving 0.5% QX-314 alone plus the AUC from the group receiving 2.0% lidocaine alone. Conversely, the value of AUC representing grip strength in the group receiving a combined dose of 0.5% QX-314 + 2% lidocaine, is less than the combined values of grip strength AUCs from the group receiving 0.5% QX-314 alone plus the grip strength AUC from the group receiving 2.0% lidocaine alone.
Similar articles
- Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers.
Binshtok AM, Bean BP, Woolf CJ. Binshtok AM, et al. Nature. 2007 Oct 4;449(7162):607-10. doi: 10.1038/nature06191. Nature. 2007. PMID: 17914397 - Acid solution is a suitable medium for introducing QX-314 into nociceptors through TRPV1 channels to produce sensory-specific analgesic effects.
Liu H, Zhang HX, Hou HY, Lu XF, Wei JQ, Wang CG, Zhang LC, Zeng YM, Wu YP, Cao JL. Liu H, et al. PLoS One. 2011;6(12):e29395. doi: 10.1371/journal.pone.0029395. Epub 2011 Dec 28. PLoS One. 2011. PMID: 22216270 Free PMC article. - Coapplication of lidocaine and the permanently charged sodium channel blocker QX-314 produces a long-lasting nociceptive blockade in rodents.
Binshtok AM, Gerner P, Oh SB, Puopolo M, Suzuki S, Roberson DP, Herbert T, Wang CF, Kim D, Chung G, Mitani AA, Wang GK, Bean BP, Woolf CJ. Binshtok AM, et al. Anesthesiology. 2009 Jul;111(1):127-37. doi: 10.1097/ALN.0b013e3181a915e7. Anesthesiology. 2009. PMID: 19512868 Free PMC article. - Differential effects of TRPV channel block on polymodal activation of rat cutaneous nociceptors in vitro.
St Pierre M, Reeh PW, Zimmermann K. St Pierre M, et al. Exp Brain Res. 2009 Jun;196(1):31-44. doi: 10.1007/s00221-009-1808-3. Epub 2009 Apr 30. Exp Brain Res. 2009. PMID: 19404626 Review. - Lighting a backfire to quench the blaze: a combined drug approach targeting the vanilloid receptor TRPV1.
Blumberg PM. Blumberg PM. Mol Interv. 2007 Dec;7(6):310-2. doi: 10.1124/mi.7.6.5. Mol Interv. 2007. PMID: 18199852 Review.
Cited by
- Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.
Bukhari M, Deng H, Jones N, Towne Z, Woodworth CD, Samways DS. Bukhari M, et al. FEBS Lett. 2015 Jun 4;589(13):1498-504. doi: 10.1016/j.febslet.2015.04.044. Epub 2015 May 1. FEBS Lett. 2015. PMID: 25937122 Free PMC article. - Imaging large-scale cellular activity in spinal cord of freely behaving mice.
Sekiguchi KJ, Shekhtmeyster P, Merten K, Arena A, Cook D, Hoffman E, Ngo A, Nimmerjahn A. Sekiguchi KJ, et al. Nat Commun. 2016 Apr 28;7:11450. doi: 10.1038/ncomms11450. Nat Commun. 2016. PMID: 27121084 Free PMC article. - Targeting peripheral afferent nerve terminals for cough and dyspnea.
Muroi Y, Undem BJ. Muroi Y, et al. Curr Opin Pharmacol. 2011 Jun;11(3):254-64. doi: 10.1016/j.coph.2011.05.006. Epub 2011 Jun 24. Curr Opin Pharmacol. 2011. PMID: 21705272 Free PMC article. Review. - Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.
Theile JW, Cummins TR. Theile JW, et al. Front Pharmacol. 2011 Oct 4;2:54. doi: 10.3389/fphar.2011.00054. eCollection 2011. Front Pharmacol. 2011. PMID: 22007172 Free PMC article. - Nano-engineered microcapsules boost the treatment of persistent pain.
Kopach O, Zheng K, Dong L, Sapelkin A, Voitenko N, Sukhorukov GB, Rusakov DA. Kopach O, et al. Drug Deliv. 2018 Nov;25(1):435-447. doi: 10.1080/10717544.2018.1431981. Drug Deliv. 2018. PMID: 29383961 Free PMC article.
References
- Ahern CA, Eastwood AL, Dougherty DA, Horn R. Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008;102:86–94. - PubMed
- Berberich G, Reader A, Drum M, Nusstein J, Beck M. A prospective, randomized, double-blind comparison of the anesthetic efficacy of two percent lidocaine with 1:100,000 and 1:50,000 epinephrine and three percent mepivacaine in the intraoral, infraorbital nerve block. J Endod. 2009;35:1498–1504. - PubMed
- Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature. 2007;449:607–610. - PubMed
- Binshtok AM, et al. Activation of TRPA1 As Well As TRPV1 Channels by Lidocaine Allows Entry of QX-314 into Nociceptors to Produce A Pain Selective Sodium Channel Block. Chikago, IL: Society for Neuroscience Meeting; 2009b.
Publication types
MeSH terms
Substances
Grants and funding
- NS064274/NS/NINDS NIH HHS/United States
- R01 NS039518/NS/NINDS NIH HHS/United States
- R01 NS064274/NS/NINDS NIH HHS/United States
- R37 NS039518/NS/NINDS NIH HHS/United States
- NS039518/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources